<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523313</url>
  </required_header>
  <id_info>
    <org_study_id>IMMUNED</org_study_id>
    <nct_id>NCT02523313</nct_id>
  </id_info>
  <brief_title>Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED</brief_title>
  <official_title>A Phase II Randomized, Double-Blind Trial of Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab Versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma With No Evidence of Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Dirk Schadendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, double-blind placebo-controlled, multicenter, randomized phase II
      trial testing the adjuvant immunotherapy with Nivolumab plus Ipilimumab Placebo or Nivolumab
      plus Ipilimumab versus Double Placebo Control as a post-surgical/post-radiation treatment for
      stage IV melanoma with no evidence of disease (NED).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will allow for direct comparison of the clinical benefit provided by Nivolumab
      monotherapy or Nivolumab combined with Ipilimumab versus double placebo control. Furthermore,
      it will also allow for direct comparison of the respective safety profiles of Nivolumab
      monotherapy or Nivolumab combined with Ipilimumab. Nivolumab monotherapy was chosen as one of
      the experimental arms because of a favourable risk-benefit ratio assessed in the large Phase
      1 study (MDX1106-03/CA209-003). The combination of Nivolumab and Ipilimumab was chosen as an
      experimental arm because of the preliminary evidence from the Phase 1 study CA209-004
      suggesting synergy between Nivolumab and Ipilimumab resulting in a higher frequency of
      patients with increased tumour burden reduction. Evaluating both Nivolumab monotherapy and
      the combination of Nivolumab and Ipilimumab will provide clinical data allowing clinicians to
      select the appropriate treatment for each patient based on their individual risk-benefit
      ratio.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of adjuvant immunotherapy with Nivolumab alone or in combination with Ipilimumab (Progression-free survival)</measure>
    <time_frame>24 months after LPI</time_frame>
    <description>Progression-free survival (PFS) defined as the time from the first study treatment date until documented tumor progression date or date of death, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months after LPI</time_frame>
    <description>Overall survival of a patient defined as the time from the first study treatment date until documented date of death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety / Toxicity All adverse events ≥ Grade 3 according to CTCAE Version 4.0 criteria</measure>
    <time_frame>until 90 days after discontinuation of dosing</time_frame>
    <description>All adverse events ≥ Grade 3 according to CTCAE Version 4.0 criteria, that are related to the administration of the investigational agents will be assessed</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab (3 mg/kg) i.v. every 2 weeks + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) i.v. every 3 weeks for 4 doses. Both study drugs are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12: Nivolumab as maintenance and at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab + Placebo</intervention_name>
    <description>Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.</description>
    <arm_group_label>Nivolumab + Placebo</arm_group_label>
    <other_name>Treatment Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab + Ipilimumab</intervention_name>
    <description>Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.</description>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <other_name>Treatment Arm B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double Placebo Control</intervention_name>
    <description>Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.</description>
    <arm_group_label>Double Placebo Control</arm_group_label>
    <other_name>Treatment Arm C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage IV melanoma arising from a primary cutaneous site or metastatic from an unknown
             primary site with no evidence of disease (NED) after surgery or radiation therapy
             (conducted within 8 weeks before enrolment)

          -  Signed written informed consent

          -  Known BRAF status

          -  Subjects must be willing and able to comply with scheduled visits, treatment schedule,
             laboratory testing, and other requirements of the study

          -  Minimum life expectancy of five years excluding their melanoma diagnosis

          -  ECOG performance status of 0 or 1

          -  Tumor tissue from the resected site of disease must be provided for biomarker
             analyses. In order to be randomized a subject must have a PD-L 1 expression
             classification (positive (≥ 5% tumor cells expressing PD-L1) or negative (&lt; 5% tumor
             cells expressing PD-L1)). If an insufficient amount of tumor tissue from the resected
             site is provided for analysis, acquisition of additional archived tumor tissue (block
             and/or slides) for the biomarker analyses is required.

          -  Prior radiotherapy must have been completed at least 2 weeks prior to study drug
             administration

          -  Required laboratory values

          -  Negative pregnancy test for female subjects and effective contraception (Pearl-Index
             &lt;1) for both male and female subjects if the risk of conception exists

        Exclusion Criteria:

          -  History of primary uveal or mucosal melanoma

          -  Prior therapy with CTLA4 or PD1 antibodies

          -  The patient has psychiatric or addictive disorders that may compromise his/her ability
             to give informed consent or to comply with the trial procedures.

          -  Lack of availability for clinical follow-up assessments.

          -  Any immunosuppressive therapy given within the past 30 days prior to study drug
             administration (excluding physiologic steroid hormone replacement)

          -  Other malignancies within the past five years requiring treatment except basal or
             squamous skin carcinomas or carcinoma in situ of the cervix

          -  Serious cardiac, gastrointestinal, hepatic or pulmonary disease reducing life
             expectancy to less than five years

          -  Patients with serious intercurrent illness, requiring hospitalization.

          -  Other serious illnesses, e.g., serious infections requiring antibiotics or bleeding
             disorders.

          -  The patient is known to be positive for Human Immunodeficiency Virus (HIV) or other
             chronic infections (HBV, HCV) or has another confirmed or suspected immunosuppressive
             or immunodeficient condition.

          -  Known hypersensitivity reaction to any of the components of study treatment

          -  Pregnancy (absence to be confirmed by ß-HCG urinary test, minimum sensitivity 25IU/L
             or equivalent units of HCG)) or lactation period

          -  Women of childbearing potential (WOCBP): Refusal or inability to use effective means
             of contraception (Pearl-Index &lt;1). WOCBP will be instructed to adhere to contraception
             until 31 weeks after the last dose of investigational product

          -  Men who are sexually active with WOCBP must use any contraceptive method with a
             failure rate of less than 1% per year (Pearl-Index &lt;1). Men receiving Nivolumab and
             who are sexually active with WOCBP will be instructed to adhere to contraception until
             31 weeks after the last dose of investigational product

          -  Known alcohol or drug abuse

          -  Participation in another clinical study and use of any investigational or
             non-registered product (drug or vaccine) within the 30 days before registration

          -  Significant disease or condition which, in the investigator's opinion, would exclude
             the patient from the study

          -  Legal incapacity or limited legal capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Schadendorf, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Studienzentrum Hautklinik Universitätsklinikum Essen (AöR) Klinik für Dermatologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk Schadendorf, Prof. Dr.</last_name>
    <phone>+49201-7234342</phone>
    <email>Dirk.Schadendorf@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jürgen C. Becker, Prof. Dr.Dr.</last_name>
    <phone>+49201-1833626</phone>
    <email>j.becker@dkfz-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Kiecker, Dr.</last_name>
      <email>felix.kiecker@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elbe Klinikum Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Mohr, Dr.</last_name>
      <email>peter.mohr@elbekliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedegund Meier, Prof. Dr.</last_name>
      <email>friedegund.meier@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Hautklinik Universitätsklinikum Essen (AöR) Klinik für Dermatologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Grimm</last_name>
      <phone>+49-201-723</phone>
      <phone_ext>2325</phone_ext>
      <email>julia.grimm@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera GmbH</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kaatz, PD Dr.</last_name>
      <email>kaatz.studienzentrum@wkg.srh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Gutzmer, Prof. Dr.</last_name>
      <email>gutzmer.ralf@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Gutzmer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Imke Satzger, Pd Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SLK Kliniken Heilbronn GmbH</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Martens, Prof. Dr.</last_name>
      <email>uwe.martens@slk-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Dippel, Prof. Dr.</last_name>
      <email>dippele@klilu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UKSH Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Terheyden, PD Dr.</last_name>
      <email>Patrick.Terheyden@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Dermatologie, Venerologie und Allergologie UMM - Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Stuppy</last_name>
      <phone>+49-621-383</phone>
      <phone_ext>3993</phone_ext>
      <email>d.stuppy@dkfz-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum München (LMU)</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carola Berking, Prof. Dr.</last_name>
      <email>carola.berking@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fachklinik Hornheide</name>
      <address>
        <city>Münster</city>
        <zip>48157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fluck, Dr.</last_name>
      <email>michael.fluck@fachklinik-hornheide.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Berneburg, Prof. Dr.</last_name>
      <email>mark.berneburg@ukr.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>November 5, 2017</last_update_submitted>
  <last_update_submitted_qc>November 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Dirk Schadendorf</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

